Assessing the Effectiveness of the SOLIO Alfa Cure Plus Device for Low Back Pain
Study Overview
Nonspecific low back pain (LBP) is a major global health issue, affecting 84% of people at some point in their lives. Of these, 23% suffer from chronic pain, which disrupts daily activities. The SOLIO Alfa Cure Plus device, designed to provide low-level laser therapy, radio frequency, and heat, aims to alleviate this chronic pain without needing a specific diagnosis.
Study Methodology
This study was a randomized, single-blinded, controlled trial involving 37 patients. We used the Numeric Pain Rating Scale (NPRS), the Oswestry Disability Index (ODI), and Schober’s test to measure outcomes. Patients were randomly assigned to receive either the real device or a sham device.
Key Findings
- Greater Pain Relief: The SOLIO group experienced a 42% reduction in pain compared to 23% in the sham group (p = 0.03).
- Improved Flexibility: The SOLIO group showed a 13% improvement in flexibility, while the sham group worsened by 6.5% (p = 0.04).
Conclusion
The SOLIO Alfa Cure Plus device significantly reduces back pain and enhances the quality of life for patients.
Clinical Trials Registration
Clinical trials registration number: 8475-21-SMC.
Importance of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, integrates ICD-11 standards, clinical protocols, and research into a single, user-friendly resource for healthcare providers.
Streamlining Healthcare Operations
In today’s healthcare landscape, efficiency is vital. Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, simplifying patient care management and expanding digital services.
Enhancing Patient Outcomes
By leveraging AI, clinics can improve workflows, enhance patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
